Reuters reported on April 30 that Charles Lieber, the former chair of Harvard’s chemistry department who was convicted in December 2021 under the US Department of Justice’s China Initiative, has been appointed director of i-BRAIN, the Institute for Brain Research, Advanced Interfaces and Neurotechnologies, a newly established branch of the Shenzhen Medical Academy of Research and Translation. Lab inauguration photographs are dated March 26, 2026. Lieber relocated to Shenzhen in April 2025, with the lab build-out and formal directorship rolling out across the past year.
The Lieber appointment lands the same week that Axoft, a Cambridge, Massachusetts implantable BCI company, disclosed a $55 million Series A led by Thai conglomerate Charoen Pokphand’s strategic-investment arm with Chinese co-investors, and a first acute clinical test of its Fleuron polymer probe at a Shanghai hospital. Read together, the two stories are the capital and talent legs of the same bilateral BCI flow. Asian institutional capital is taking lead positions in US implantable-BCI Series A rounds. Senior US scientific leadership in the same category is taking directorships at state-funded Chinese institutions. Both directions are running concurrently this week.
What the Shenzhen lab does
The disclosed research focus at i-BRAIN is direct continuation of Lieber’s pre-conviction Harvard work: flexible, neuro-compatible electronic mesh that can be delivered into brain tissue via syringe injection, intended to integrate with neural micro-vasculature without the chronic foreign-body response that limits rigid electrode arrays. The institutional infrastructure available to Lieber at i-BRAIN materially exceeds what he had access to at Harvard. Dedicated nanofabrication equipment, advanced lithography systems, and primate research facilities at scale are all in-house at the Shenzhen site. The parent Shenzhen Medical Academy of Research and Translation has increased its 2026 budget substantially, with reporting referencing figures around $153 million for the fiscal year, and operates within a broader Shenzhen state-backed science hub funded at the multi-billion-dollar level.
How this fits China’s BCI policy
China designated brain-computer interfaces as a national growth priority in its 2026 five-year plan. That policy package also includes the NMPA approval pathway used by Neuracle for the world’s first commercial implantable BCI clearance in March, and the National Healthcare Security Administration’s April 23 government-guided pricing for invasive BCI procedures at 6,000–6,600 yuan per implantation, with provincial implementation now rolling out in Sichuan, Hubei, and Zhejiang. The state policy stack now connects research infrastructure at i-BRAIN, regulatory approval at the NMPA, reimbursement framework at the NHSA, and clinical deployment at the provincial level. Lieber’s directorship at i-BRAIN sits at the research-infrastructure layer of that stack, which prior to this announcement had been the least-internationalised layer.
The Lieber background
Lieber was convicted in December 2021 of making false statements to federal investigators about his ties to the Thousand Talents Plan, a Chinese government talent-recruitment programme, and of tax offences relating to undisclosed compensation and an undisclosed Wuhan University of Technology bank account. He served two days in prison, six months of house arrest, paid a $50,000 fine, and paid $33,600 in IRS restitution. He had been Harvard’s chemistry department chair and was widely cited as a leading figure in nanowire-based bioelectronics, which forms the technical foundation of his current i-BRAIN work. The case was prosecuted under the US Department of Justice’s China Initiative, a programme formally wound down in February 2022 amid concerns about its scope and prosecutorial outcomes.
What it signals for the BCI category
Three observations on what this means for the BCI category. First, the prosecution of Lieber under the China Initiative did not deter the underlying research collaboration. It relocated and concentrated it. Whatever capability gap the prosecution intended to maintain has been closed, with the additional consequence that the research now sits institutionally inside Chinese state infrastructure rather than distributed across US-China academic ties. Second, the scale of the Shenzhen infrastructure available to Lieber is qualitatively different from the distributed US academic model. Primate facilities, nanofabrication, and lithography concentrated at one institution under one director compresses development timelines in a way that no individual US university can match. Third, the question to track over the next twelve to eighteen months is whether other senior researchers in adjacent BCI categories follow the Lieber path, and what the cumulative effect of those decisions is on the US BCI talent base. The trajectory continues. The question is at what rate.
The Lieber-i-BRAIN story, the Axoft Series A on the capital side, and the NHSA pricing rollout on the regulatory side give the BCI category three concurrent data points on bilateral flows in a single week. The strategic question for any operator with implantable-BCI exposure has shifted, from whether the bilateral dynamic exists to which side of which flow they are positioned on.